COMMUNIQUÉS West-GlobeNewswire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19/01/2024
SAN CARLOS, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
19/01/2024
Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement FOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/01/2024
MALVERN, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that [...]
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/01/2024
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/01/2024
NOVATO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
19/01/2024
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 [...]
ONWARD® to Participate in Degroof Petercam Healthcare Conference
19/01/2024
CEO Dave Marver will provide update on the Company’s progress toward launch of its first therapy later this year EINDHOVEN, the Netherlands, Jan. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the [...]
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
19/01/2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the reinspection of Alvotech’s facility in Iceland [...]
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
19/01/2024
Company announcement – No. 5 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 19 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78 [...]
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
19/01/2024
REYKJAVIK, Iceland, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Change of management at NTG Nordic Transport Group A/S
19/01/2024
Company announcement no. 1 – 24 19 January 2024 Change of management at NTG Nordic Transport Group A/S The board of directors accommodates the wish of Group CEO, Michael Larsen, to transition into a more operational [...]
FDA grants global Medical Device company Biomimetic Innovations ‘Breakthrough Device’ designation for OsStic® Synthetic Injectable Structural Bio-Adhesive Bone Void Filler
19/01/2024
SHANNON, Ireland, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd today announced that OsStic ® has been granted ‘Breakthrough Device’ designation by the FDA. The proposed indication statement for this [...]
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
19/01/2024
In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2 and 3 advanced [...]
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
19/01/2024
TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
Strainsforpains, Inc. secures its largest orders to date from NYC establishments
19/01/2024
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. Announces Corporate Update (Strainsforpains, Inc.) (OTC Markets: EBYH). Strainsforpains, Inc. is pleased to announce it has closed out 2023 with its [...]
United Health Products Reports on FDA Application Status
19/01/2024
MESQUITE, NV, Jan. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – United Health Products (UEEC) reports today on the receipt and review of final reports on product sterilization and stability testing for its hemostatic [...]
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
19/01/2024
- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator - - Project NextGen is a $5 billion initiative by the U.S. Department of [...]
SteveWillDoIt Does Safety Shot: One of the Top Influencers on Social Media Partners with Safety Shot, a Wellness Beverage that Reduces Blood Alcohol & Boosts Clarity
19/01/2024
Long-term partnership to help Safety Shot drive brand awareness and significant revenue quickly JUPITER, FL, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) today announced that Steve Deleonardis, [...]
Extendicare Announces Timing of 2023 Fourth Quarter Results and Conference Call
19/01/2024
MARKHAM, Ontario, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the fourth quarter of 2023 after market [...]

Pages